ROAD TO THE CURE UPDATE MARCH 2014Category: Road to the Cure
Just as we were going to press, we received information that one of the SDBC’s Canadian collaborators has shown that the iodine -125 labeled alpha-synuclein SM penetrated the Blood Brain Barrier in the brain of the mice. The historic validation of this science further confirms its place at the forefront of the reversal of Parkinson’s disease, albeit there is still much optimization needed to be done. The goal, at this juncture, was to show the proof-of-principle which has now been completed. Huge congratulations go to the scientists.
To further the discussion, stem cell technology holds a great potential for treating Parkinson’s disease as it has been shown in many studies outside the U.S. whereby patients are benefited from stem cells transplantation or even transfusion. However, different studies point to differing results in terms of their effectiveness and the duration of stem cell treatment. So far, the U.S. FDA has not authorized a clinical trial of stem cells transplantation to treat Parkinson’s disease. The Scientific Community agrees that the following questions need to be addressed:
- How to grow large quantities of dopamine-producing nerve cells?
- How to deal with graft induced dyskinesia?
- How to make sure new nerve cells survive in an environment that has already killed neurons and retain their phenotype for a long term?
- How to get transplanted cells to connect and work normally inside the brain?
- How to prevent newly transplanted cells from forming tumors?
Logic dictates that any therapy for treating Parkinson’s disease must include:
- Early diagnosis for early intervention for saving neurons from toxic pathogens
- Therapy to clear toxic protein aggregates that are deleterious to brain cells
- Therapy to replenish dead cells in cases where most neurons are compromised
The San Diego Biotech Company (SDBC), is developing technology for early diagnosis and treatment to address the pathological mechanism responsible for the death of dopaminergic neurons. The Company believes that it will have a diagnostic test for Parkinson’s disease very soon. Its therapeutic approach would change the status of neuro-inflammation which may be a contributing factor for the neuron degeneration. The SDBC’s therapeutic approach will also be impedance (obstruction or opposition to passage or flow, as of an electric current or other form of energy) for long term survival of transplanted stem cells. It is hoped that their multi-targeted smart molecules will help address and provide an environment conducive for solving the major challenges of stem cells as mentioned above.
In short, the stem cell treatment provides a great hope for millions of patients but it does not correct the pathology of Parkinson’s disease. In other words, it does not eradicate the toxins responsible for killing the neurons in the first place. Without modifying the disease, PLACEBO affect alone can make the patient feel euphoric for some time, which invariably results in disappointment. That is why there is an urgent need to develop blood-brain barrier permeable drugs that can scavenge/eliminate the pathogens responsible for neuronal death. Earlier detection and therapeutic intervention can save the patient from debilitation. This is exactly what the SDBC is committed to do.
The SDBC approach looks promising to stop and/or reverse the disease processes and provide an environment favorable to the survival and growth of transplanted cells, since before the stem cell transplantation can be fully effective, the process of eradicating the toxins must take place. The news that the Blood Brain Barrier has been penetrated successfully means that the SDBC research is on the right track and that the science is advancing toward a real cure for Parkinson’s disease.
To speed this science along, the SDBC needs funding. They hold an opportunity for someone to invest in history, humanity and potential eradication of a disease that affects around 6.5 million people.